Pmec 1%10 gm

Pmec 1% is a topical calcineurin inhibitor indicated for the treatment of mild-to-moderate atopic dermatitis (eczema).

Established (FDA-approved) use

• Second-line, short-term treatment of mild-to-moderate atopic dermatitis in non-immunocompromised patients 2 years of age and older who have not responded adequately to, or who cannot tolerate, other treatments (such as topical corticosteroids).
• Non-continuous long-term (intermittent) treatment to prevent disease flares, under physician supervision.

Particularly useful for

• Sensitive skin areas such as the face, eyelids, neck, and skin folds (axillae, groin), where prolonged topical corticosteroid use carries a risk of skin thinning (atrophy).

Pmec 1% is not a first-line treatment and is not indicated for other skin conditions unless specifically advised by a physician.

Each gram of topical Pimecrolimus cream contains 10 mg (1% w/w) of Pimecrolimus as the active ingredient, in a non-greasy cream base.

Pmec 1% is a non-steroidal topical calcineurin inhibitor used in dermatology for the anti-inflammatory management of atopic dermatitis. It was developed as a steroid-sparing alternative for sensitive skin sites and for patients who need treatment without the cumulative skin-thinning risk associated with long-term topical corticosteroid use.

Pmec 1% is supplied as a 1% topical cream for external use on the skin only. It is not for ophthalmic, oral, or intravaginal use.

Topical Calcineurin Inhibitor (non-steroidal topical immunomodulator/anti-inflammatory agent)

Pimecrolimus is an ascomycin macrolactam derivative that selectively binds to macrophilin-12 (FKBP-12) in T-lymphocytes. This complex inhibits the phosphatase calcineurin, blocking the dephosphorylation of nuclear factor of activated T-cells (NF-AT).

As a result, Pimecrolimus prevents the transcription and release of pro-inflammatory cytokines (such as interleukin-2, interleukin-4, interferon-gamma, and TNF-alpha) from activated T-cells and mast cells, thereby reducing the inflammatory cascade underlying atopic dermatitis without the collagen synthesis inhibition seen with topical corticosteroids.

Following topical application, systemic absorption of Pimecrolimus is minimal to undetectable in most patients.

For external (topical) use on the skin only.

• Wash and dry hands before and after application (unless hands are the treated area).
• Apply a thin layer of Pmec 1% to cover only the affected skin; rub in gently and completely.
• Avoid contact with eyes, mouth, nose, and vaginal mucosa; if accidental contact occurs, wipe off and/or rinse with water.
• Do not bathe, shower, or swim immediately after application, as this may wash off the medicine.
• Do not cover the treated area with airtight/occlusive dressings or bandages unless directed by a physician.
• Avoid excessive sun exposure, sunlamps, or tanning beds during treatment; use sun-protective clothing or sunscreen if sun exposure cannot be avoided.

Systemic absorption of Pmec 1% after topical application is minimal, so clinically significant drug interactions are uncommon. However, the following should be noted:

• Other topical products: Avoid applying other topical medicines (including corticosteroids) to the same skin area at the same time unless directed by a physician, as combined effects have not been studied.
• Ultraviolet (UV) light/phototherapy: Concurrent use with UV therapy (including phototherapy for psoriasis or other conditions) is not recommended, as the combined immunosuppressive/photocarcinogenic risk has not been established (see Precautions and Warnings for malignancy risk).
• CYP3A4 inhibitors (systemic): A theoretical interaction exists in patients with extensive body-surface-area involvement or in infants/young children applying Pmec 1% over large areas while taking strong systemic CYP3A4 inhibitors, due to a small but measurable potential for increased systemic exposure; use with caution in such cases.

The most common adverse reaction associated with Pmec 1% is a mild-to-moderate sensation at the application site.

Very common

• Application-site burning, stinging, or warmth (usually mild and decreases with continued use)

Common

• Application-site irritation, erythema, or pruritus
• Headache
• Nasopharyngitis (common cold symptoms)
• Influenza-like illness
• Cough

Uncommon/rare

• Folliculitis or worsening of atopic dermatitis
• Skin papilloma/warts
• Hypersensitivity reactions (rash, swelling)

Patients should notify their physician if application-site reactions are severe, persistent, or if signs of skin infection develop.

Pregnancy: Systemic absorption of Pmec 1% after topical application is minimal. However, adequate and well-controlled studies in pregnant women are lacking. Pmec 1% should be used during pregnancy only if clearly needed and if the potential benefit justifies the potential risk to the fetus; a physician should be consulted before use.

Lactation: It is not known whether topically applied Pmec 1% is excreted in human breast milk in clinically significant amounts. Caution should be exercised when Pmec 1% is used by a breastfeeding woman, particularly avoiding application to the breast/nipple area to prevent direct infant ingestion. Consult a physician before use while breastfeeding.

Boxed warning: theoretical risk of malignancy

Although a causal relationship has not been established in humans, rare cases of malignancy (including skin cancers and lymphoma) have been reported in patients treated with topical calcineurin inhibitors such as Pmec 1%, and long-term safety data are limited. Based on this signal:

• Pmec 1% is not recommended for use in immunocompromised patients or children under 2 years of age.
• Pmec 1% should be used for the shortest duration consistent with effective disease control; continuous long-term use should be avoided.
• Pmec 1% should only be used after other available treatment options have failed or are not tolerated.

Other precautions

• Sun exposure: Avoid excessive exposure to sunlight, sunlamps, or tanning beds during treatment; use appropriate sun protection.
• Skin infections: Do not apply to skin with active bacterial or viral infections until the infection has cleared, as Pmec 1% may mask signs of infection or theoretically increase susceptibility.
• Lymphadenopathy: If lymph node enlargement develops during treatment, investigate the cause; discontinue Pmec 1% if a clear cause (e.g., infection) is not identified or if acute infectious mononucleosis is present.
• Generalized erythroderma: Use with caution as it may increase systemic exposure.
• Pmec 1% is not an antibiotic and has no role in treating bacterial or fungal skin infections.

Topical overdose (excessive application) of Pmec 1% may increase the risk of local skin irritation. Accidental ingestion is unlikely to cause serious toxicity given minimal systemic absorption, but is not recommended.

If excessive application, accidental ingestion (especially by a child), or a severe/allergic reaction occurs, seek immediate medical attention or contact a poison control center/emergency services rather than attempting home treatment.

Store at room temperature (below 30°C), away from direct light and moisture. Do not freeze. Keep the tube tightly closed and out of the reach and sight of children.

Pediatric use

Pmec 1% is approved for patients 2 years of age and older. Safety and efficacy in children under 2 years have not been established, and use in this age group is not recommended (see Pediatric Use for details).

Elderly (geriatric) use

Clinical studies of Pmec 1% did not include sufficient numbers of patients aged 65 and over to determine if they respond differently from younger patients; use with routine caution.

Renal/hepatic impairment

Given minimal systemic absorption after topical application, no dose adjustment is typically required for renal or hepatic impairment; specific studies in these populations are limited.

Immunocompromised patients

Use is not recommended in patients with a weakened immune system (see Contraindications and Precautions and Warnings).

Pmec 1% should be applied until signs and symptoms of atopic dermatitis have resolved. If there is no improvement within 6 weeks, the patient should be re-evaluated by a physician to confirm the diagnosis. For long-term management, Pmec 1% may be used intermittently (non-continuously) at the first signs of a flare, under physician supervision, but continuous long-term daily use should be avoided given the theoretical malignancy risk (see Precautions and Warnings).

Topical Calcineurin Inhibitors (TCIs); Topical Immunomodulators; Dermatological Anti-inflammatory Agents

Pimecrolimus binds to the intracellular receptor macrophilin-12, inhibiting calcineurin phosphatase activity. This blocks the dephosphorylation and nuclear translocation of NF-AT, preventing T-cell activation and suppressing the synthesis and release of pro-inflammatory cytokines (IL-2, IL-4, interferon-gamma, TNF-alpha) that drive the inflammatory skin response in atopic dermatitis.

C

Pmec 1% is approved for the treatment of mild-to-moderate atopic dermatitis in children 2 years of age and older, using the same twice-daily application regimen as adults, applied only to affected skin areas.

Under 2 years of age: Safety and efficacy of Pmec 1% have not been established in infants and children below 2 years, and its use is not recommended in this age group due to concerns about an immature immune system and the theoretical malignancy signal associated with topical calcineurin inhibitors.

Parents/caregivers should use the minimum amount needed to control symptoms and consult a pediatrician regularly during treatment.